Drug
Patiromer clinical trials
Also written Veltassa and RLY5016.
- studies test it
- 25
- open now
- 3
- in phase 3
- 6
- first study started
- 2008
Keep track of what changes. Save the patiromer studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
- Veltassa
- 12
Development codes
Studies by the year they started
25 studies that test it; most in 2017 (4)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2013 | 1 |
| 2016 | 2 |
| 2017 | 4 |
| 2018 | 1 |
| 2019 | 4 |
| 2020 | 3 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 9
- Phase 3
- 6
- Phase 4
- 10
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 13 · Other 12
Relypsa, Inc. (7) · Vifor Pharma, Inc. (3) · Mario Negri Institute for Pharmacological Research (2) · Vifor Fresenius Medical Care Renal Pharma (1) · Duke University (1) · Wake Forest University Health Sciences (1) · Dominic Raj (1) · Oslo University Hospital (1)
Often tested with
Tested in the same studies.
Spironolactone (1) · Polyethylene glycol 3350 (1) · Polyethylene Glycols (1) · Polystyrene sulfonic acid (1) · Sodium zirconium cyclosilicate (1)
Studies
Open first, then newest update. How each study uses patiromer is read from its arms, and is right about nine times in ten.
Testing it · 25
- Effect of Patiromer in Children Under 12 Years of Age With High Blood Potassium LevelsRecruitingPhase 2Vifor Pharma, Inc.NCT05766839Written as Patiromer
- Potassium Correction for RAAS Optimization in Chronic Kidney DiseaseRecruitingPhase 4University Medical Center GroningenNCT06256991Written as Patiromer 8400 MG [Veltassa]
- Patiromer and Diet/hrQoL in Chronic DialysisRecruitingPhase 3Mario Negri Institute for Pharmacological ResearchNCT06858280Written as Patiromer 8400 MG [Veltassa]
- Comparison of Potassium Binders in the ERTerminatedPhase 4University of California, IrvineNCT04585542Written as Patiromer
- Trial Evaluating the Efficacy and Safety of Patiromer in Chinese SubjectsCompletedPhase 3Vifor Fresenius Medical Care Renal PharmaNCT05136664Written as Patiromer Powder for Oral Suspension (Part A)
- Patiromer Efficacy to Reduce Episodic Hyperkalemia in End Stage Renal Disease PatientsCompletedPhase 4Duke UniversityNCT03781089Written as Patiromer Oral Powder Product
- RELieving Increasing oEdema Due to Heart FailureTerminatedPhase 4NHS Greater Glasgow and ClydeNCT04142788Written as Patiromer
- Patiromer Trial in CKD Stage IIIB to VTerminatedPhase 3Mario Negri Institute for Pharmacological ResearchNCT05786469Written as Veltassa Oral Powder Product
- Patiromer Utility as an Adjunct Treatment in Patients Needing Urgent Hyperkalemia ManagementTerminatedPhase 4Comprehensive Research AssociatesNCT04443608Written as Patiromer Powder for Oral Suspension [Veltassa]
- A Pilot Trial of Twice-weekly Versus Thrice-weekly Hemodialysis in Patients With Incident End-stage Kidney DiseaseCompletedPhase 3Wake Forest University Health SciencesNCT03740048Written as Patiromer Oral Product
- The Effects of Patiromer on Serum Potassium Level and Gut Microbiome of ESRD Patients With HyperkalemiaCompletedPhase 2Dominic RajNCT03326583Written as Patiromer
- Effects of Patiromer on Pharmacokinetics of Immunosuppresive Drugs in Renal Transplant RecipientsCompletedPhase 4Oslo University HospitalNCT05029310Written as Patiromer Oral Product
- Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND)CompletedPhase 3Vifor Pharma, Inc.NCT03888066Written as Patiromer
- Pharmacodynamic & Safety of Patiromer in Children & Adolescents (2-<18 Yrs) With Chronic Kidney Disease and HyperkalemiaTerminatedPhase 2Vifor Pharma, Inc.NCT03087058Written as Patiromer
- Use of Patiromer to Transition Chronic Kidney Disease Patients With Hyperkalemia to a Plant-rich Diet.CompletedPhase 4NYU Langone HealthNCT03183778Written as Patiromer
- A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia (OPAL)CompletedPhase 3Relypsa, Inc.NCT01810939Written as Patiromer
- Patiromer in the Treatment of Hyperkalemia in Patients With Hypertension and Diabetic Nephropathy (AMETHYST-DN)CompletedPhase 2Relypsa, Inc.NCT01371747Written as patiromer
- Evaluation of Patiromer in Heart Failure PatientsCompletedPhase 2Relypsa, Inc.NCT00868439Written as patiromer
- Patiromer With or Without Food for the Treatment of HyperkalemiaCompletedPhase 4Relypsa, Inc.NCT02694744Written as patiromer
- Spironolactone With Patiromer in the Treatment of Resistant Hypertension in Chronic Kidney DiseaseCompletedPhase 2Relypsa, Inc.NCT03071263Written as Patiromer
Codes
What other systems call patiromer · ClinicalTrials.gg INT005946
- MeSH (NLM) C568789patiromerOne source NLM
- UNII (FDA) 1FQ2RY5YHHPATIROMERConfirmed FDA, NLM, Wikidata
- RxNorm 1716203Confirmed FDA, Wikidata
- Wikidata Q21284261patiromerConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C166500PatiromerOne source FDA
- DrugBank DB09263One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C568789 | patiromer | One source NLM |
| UNII (FDA) | 1FQ2RY5YHH | PATIROMER | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1716203 | — | Confirmed FDA, Wikidata |
| Wikidata | Q21284261 | patiromer | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C166500 | Patiromer | One source FDA |
| DrugBank | DB09263 | — | One source Wikidata |
Also registered as patiromer calcium (UNII 7T97I3787N) and patiromer sorbitex calcium (UNII 0LB9J2797D · RxNorm 2204723).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.